DBV Technologies SA (DBVT)
13.61
+0.19
(+1.42%)
USD |
NASDAQ |
Sep 02, 16:00
13.61
0.00 (0.00%)
After-Hours: 18:49
DBV Technologies Research and Development Expense (TTM) : 117.13M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 117.13M |
| March 31, 2026 | 120.40M |
| December 31, 2025 | 107.67M |
| September 30, 2025 | 96.40M |
| June 30, 2025 | 91.83M |
| March 31, 2025 | 83.24M |
| December 31, 2024 | 83.73M |
| September 30, 2024 | 92.99M |
| June 30, 2024 | 86.68M |
| March 31, 2024 | 78.48M |
| Date | Value |
|---|---|
| December 31, 2023 | 73.88M |
| September 30, 2023 | 68.92M |
| June 30, 2023 | 67.31M |
| March 31, 2023 | 69.32M |
| December 31, 2022 | 65.26M |
| September 30, 2022 | 53.83M |
| June 30, 2022 | 55.83M |
| March 31, 2022 | 58.57M |
| December 31, 2021 | 70.31M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Cellectis SA | 82.95M |
| Akari Therapeutics Plc | 4.869M |
| EDAP TMS SA | -- |
| Autolus Therapeutics Plc | 112.42M |
| Evaxion AS | 10.27M |